{"id":385020,"date":"2020-11-19T08:33:38","date_gmt":"2020-11-19T13:33:38","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=385020"},"modified":"2020-11-19T08:33:38","modified_gmt":"2020-11-19T13:33:38","slug":"cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/","title":{"rendered":"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Webcast to Include Presentation by Steering Committee Co-Chair John H. Alexander, MD, MHS Highlighting Clinical Trial Progress<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p \/>\n<p \/>\n<p \/>\n<p>\n        <span class=\"xn-location\">ATLANTA<\/span>, <span class=\"xn-chron\">Nov. 19, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0<b>CryoLife, Inc. (NYSE: CRY)<\/b>, a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for investors and analysts to discuss progress with the Company&#8217;s ongoing PROACT Xa trial on <span class=\"xn-chron\">December 7, 2020<\/span> at <span class=\"xn-chron\">4:00 p.m. EST<\/span>. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/324116\/cryolife__inc__logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/324116\/cryolife__inc__logo.jpg\" title=\"Cryolife logo. (PRNewsFoto\/CryoLife, Inc.) (PRNewsFoto\/CRYOLIFE_ INC_) (PRNewsFoto\/CRYOLIFE, INC.)\" alt=\"Cryolife logo. (PRNewsFoto\/CryoLife, Inc.) (PRNewsFoto\/CRYOLIFE_ INC_) (PRNewsFoto\/CRYOLIFE, INC.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The webcast will include brief remarks by <span class=\"xn-person\">Pat Mackin<\/span>, Chairman, President, and Chief Executive Officer of CryoLife Inc. followed by a presentation from Dr. <span class=\"xn-person\">John H. Alexander<\/span>, Steering Committee Co-Chair of the PROACT Xa trial and Professor of Medicine at <span class=\"xn-org\">Duke University<\/span>, and a Q&amp;A session. <\/p>\n<p>The PROACT Xa clinical trial is a prospective, multicenter, randomized, clinical trial to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban (Eliquis<sup>\u00ae<\/sup>) rather than on warfarin. \u00a0Patient enrollment in the trial began earlier this year and is expected to continue through 2021. <\/p>\n<p>To listen to the live teleconference and participate in the Q&amp;A session, please dial 201-689-8261 a few minutes prior to <span class=\"xn-chron\">4:00 p.m. ET<\/span>.\u00a0 A replay of the teleconference will be available <span class=\"xn-chron\">December 7 through December 14, 2020<\/span> and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.\u00a0 The conference number for the replay is 13713375.<\/p>\n<p>The listen-only live webcast and replay can be accessed in the Investor Relations section of the CryoLife website at <a href=\"http:\/\/www.cryolife.com\" rel=\"nofollow\">www.cryolife.com<\/a> and selecting Webcasts &amp; Presentations.\u00a0 <\/p>\n<p>\n        <b>About the PROACT Xa Clinical Trial<br \/><\/b>The PROACT Xa trial is a prospective, multicenter, randomized clinical trial that will include approximately 1,000 participants (500 participants in each arm) at up to 60 sites in the U.S., who are 18 years of age or older and have been implanted with the On-X Aortic Valve.\u00a0 Participants will be randomized to either continue warfarin or switch to apixaban.\u00a0 Each participant will be followed for at least 2 years.\u00a0 The co-primary efficacy endpoints are to (1) determine if apixaban is non-inferior to warfarin (INR target range 2.0 &#8211; 3.0) for patients with an On-X Aortic Valve for the primary composite outcome of valve thrombosis and valve-related thromboembolism and (2) determine if apixaban provides acceptable anticoagulation for patients with an On-X Aortic Valve for the primary composite outcome of valve thrombosis and valve-related thromboembolism as compared with objective performance criteria.\u00a0 The primary safety endpoint is to determine if apixaban is superior to warfarin (INR target range 2.0 &#8211; 3.0) in the safety outcome of major bleeding in participants with an On-X Aortic Valve.<\/p>\n<p>Worldwide, there are approximately 340,000 surgical aortic valves replaced annually placing the worldwide aortic surgical valve market at approximately <span class=\"xn-money\">$1.2 billion<\/span>.<\/p>\n<p>ELIQUIS is a registered trademark of Bristol-Myers Squibb Company.\u00a0 Neither CryoLife nor the PROACT Xa Trial are affiliated with, sponsored, or endorsed by the Bristol-Myers Squibb Company.<\/p>\n<p>The PROACT Xa rationale and study design manuscript was published by Jawitz et al. in the American Heart Journal (<span class=\"xn-chron\">September 2020<\/span>). <\/p>\n<p>\n        <b>About CryoLife<br \/><\/b>Headquartered in suburban <span class=\"xn-location\">Atlanta, Georgia<\/span>, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair.\u00a0 CryoLife markets and sells products in more than 100 countries worldwide.\u00a0 For additional information about CryoLife, visit our website, <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2987215-1&amp;h=3139562208&amp;u=http%3A%2F%2Fwww.cryolife.com%2F&amp;a=www.cryolife.com\" rel=\"nofollow noopener noreferrer\">www.cryolife.com<\/a>.<\/p>\n<p>\n        <b>Contacts:<\/b>\n      <\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnbcc\">\n<tr>\n<td class=\"prnvab prnpl6 prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>CryoLife \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">D. Ashley Lee\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Executive Vice President, Chief Financial Officer <br \/>and Chief Operating Officer\u00a0 <br \/>Phone: 770-419-3355<\/span>\n              <\/p>\n<\/td>\n<td class=\"prnvat prnpl6 prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Gilmartin Group LLC<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Brian Johnston\u00a0\/ Lynn Lewis <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Phone:\u00a0 631-807-1986<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <a target=\"_blank\" href=\"mailto:investors@cryolife.com\" class=\"prnews_a\" rel=\"nofollow noopener noreferrer\">investors@cryolife.com<\/a><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CL97300&amp;sd=2020-11-19\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020-301176974.html\">http:\/\/www.prnewswire.com\/news-releases\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020-301176974.html<\/a><\/p>\n<p>SOURCE  CryoLife, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CL97300&amp;Transmission_Id=202011190830PR_NEWS_USPR_____CL97300&amp;DateId=20201119\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Webcast to Include Presentation by Steering Committee Co-Chair John H. Alexander, MD, MHS Highlighting Clinical Trial Progress PR Newswire ATLANTA, Nov. 19, 2020 \/PRNewswire\/ &#8212;\u00a0CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for investors and analysts to discuss progress with the Company&#8217;s ongoing PROACT Xa trial on December 7, 2020 at 4:00 p.m. EST. The webcast will include brief remarks by Pat Mackin, Chairman, President, and Chief Executive Officer of CryoLife Inc. followed by a presentation from Dr. John H. Alexander, Steering Committee Co-Chair of the PROACT Xa trial and Professor of Medicine at Duke University, and a Q&amp;A session. The PROACT Xa clinical trial &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-385020","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Webcast to Include Presentation by Steering Committee Co-Chair John H. Alexander, MD, MHS Highlighting Clinical Trial Progress PR Newswire ATLANTA, Nov. 19, 2020 \/PRNewswire\/ &#8212;\u00a0CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for investors and analysts to discuss progress with the Company&#8217;s ongoing PROACT Xa trial on December 7, 2020 at 4:00 p.m. EST. The webcast will include brief remarks by Pat Mackin, Chairman, President, and Chief Executive Officer of CryoLife Inc. followed by a presentation from Dr. John H. Alexander, Steering Committee Co-Chair of the PROACT Xa trial and Professor of Medicine at Duke University, and a Q&amp;A session. The PROACT Xa clinical trial &hellip; Continue reading &quot;CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T13:33:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/324116\/cryolife__inc__logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020\",\"datePublished\":\"2020-11-19T13:33:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/\"},\"wordCount\":597,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/324116\\\/cryolife__inc__logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/\",\"name\":\"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/324116\\\/cryolife__inc__logo.jpg\",\"datePublished\":\"2020-11-19T13:33:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/324116\\\/cryolife__inc__logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/324116\\\/cryolife__inc__logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/","og_locale":"en_US","og_type":"article","og_title":"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020 - Market Newsdesk","og_description":"Webcast to Include Presentation by Steering Committee Co-Chair John H. Alexander, MD, MHS Highlighting Clinical Trial Progress PR Newswire ATLANTA, Nov. 19, 2020 \/PRNewswire\/ &#8212;\u00a0CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for investors and analysts to discuss progress with the Company&#8217;s ongoing PROACT Xa trial on December 7, 2020 at 4:00 p.m. EST. The webcast will include brief remarks by Pat Mackin, Chairman, President, and Chief Executive Officer of CryoLife Inc. followed by a presentation from Dr. John H. Alexander, Steering Committee Co-Chair of the PROACT Xa trial and Professor of Medicine at Duke University, and a Q&amp;A session. The PROACT Xa clinical trial &hellip; Continue reading \"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T13:33:38+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/324116\/cryolife__inc__logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020","datePublished":"2020-11-19T13:33:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/"},"wordCount":597,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/324116\/cryolife__inc__logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/","name":"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/324116\/cryolife__inc__logo.jpg","datePublished":"2020-11-19T13:33:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/324116\/cryolife__inc__logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/324116\/cryolife__inc__logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=385020"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385020\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=385020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=385020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=385020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}